MCID: LYM022
MIFTS: 54

Lymphangioma

Categories: Cancer diseases, Cardiovascular diseases, Immune diseases, Rare diseases

Aliases & Classifications for Lymphangioma

MalaCards integrated aliases for Lymphangioma:

Name: Lymphangioma 12 36 29 54 44 15 70
Lymphatic Malformation 36 29 39
Congenital Lymphangioma 12
Lymphatic Malformations 20
Benign Lymphangioma 12
Lymphangiomas 20

Classifications:



External Ids:

Disease Ontology 12 DOID:1475
ICD9CM 34 228.1
MeSH 44 D008202
NCIt 50 C8965
SNOMED-CT 67 154625006
ICD10 32 D18.1
UMLS 70 C0024221

Summaries for Lymphangioma

GARD : 20 Lymphatic malformations or lymphangiomas are benign (non-cancerous) vascular lesions made of fluid-filled spaces (cysts) thought to occur due to abnormal development of the lymphatic system. In general, lymphatic malformations are categorized into macrocystic, microcystic, or combined depending on the size of the cysts; they are also classified in superficial lesions known as lymphangioma circumscriptum, and more deep-seated lesions (cavernous lymphangioma and cystic hygroma ). They are present at birth, although they may be discovered later in life. They are most commonly located in the neck and axilla, but they also occur in the mouth, arm, mediastinum, lung, leg, abdomen and viscera. Some may appear as a tiny blue or red spot while others are massive and affect an entire arm or leg. The signs and symptoms vary depending on the size and location of the mass; however, lymphangiomas can disfigure affected areas and disrupt the function of nearby organs or tissues. The exact underlying cause is unknown. Treatment options vary based on the signs and symptoms present in each person but may include surgery.

MalaCards based summary : Lymphangioma, also known as lymphatic malformation, is related to capillary lymphangioma and cystic lymphangioma. An important gene associated with Lymphangioma is PDPN (Podoplanin), and among its related pathways/superpathways are MAPK signaling pathway and Focal adhesion. The drugs Picibanil and Sodium citrate have been mentioned in the context of this disorder. Affiliated tissues include endothelial, tongue and pancreas, and related phenotypes are Decreased cell migration and Decreased cell migration

Disease Ontology : 12 A benign vascular tumor that is composed of dilated lymphatic channels.

KEGG : 36 Lymphangiomas are congenital malformations of the lymphatic system, which is located mostly on the head and neck region. The lesions consist of dilated endothelium-lined spaces that vary in size from microscopic channels (cavernous lymphangioma) to large cysts (cystic hygroma). Although histologically benign, these lesions may expand into surrounding tissues and/or infiltrate vital structures similar to malignancies, sometimes causing life-threatening complications. The etiology of lymphangioma is not certain. The presence of lymphatic endothelial cell (LEC)-specific markers on the endothelial lining of lymphangiomas (e.g. the transcription factor Prox1) indicates that the neoplasm may result from transformed LECs and/or stromal cells. This transformation is modulated by VEGF-C, a specific lymphatic endothelial growth factor, and its receptor VEGFR-3.

Wikipedia : 73 Lymphangiomas are malformations of the lymphatic system characterized by lesions that are thin-walled... more...

Related Diseases for Lymphangioma

Diseases related to Lymphangioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 767)
# Related Disease Score Top Affiliating Genes
1 capillary lymphangioma 32.8 PROX1 PECAM1 PDPN LYVE1 FLT4 CD34
2 cystic lymphangioma 32.6 SERPINA3 PROX1 PIK3CA PECAM1 PDPN IFNG
3 colonic lymphangioma 32.5 PECAM1 PDPN CD34
4 orbital lymphangioma 32.4 PDPN FLT4 EGFR
5 infantile myofibromatosis 31.9 VIM MIR143 CD34 ACTC1
6 lymphangiectasis 31.4 VIM ACTC1
7 kaposi sarcoma 31.1 VEGFA PIK3CA IFNA2 CD34
8 cavernous hemangioma 31.0 VIM PECAM1 KDR CD34
9 intussusception 31.0 VEGFA PECAM1 KDR CD34
10 hereditary lymphedema i 31.0 VEGFC PROX1 PDPN FLT4 CCR6
11 sarcoma 30.9 VIM VEGFA PIK3CA KDR FLT4 ACTC1
12 hydrocele 30.9 VEGFA PECAM1 FLT4
13 spindle cell sarcoma 30.9 VIM VEGFA SERPINA3 CD34 ACTC1
14 benign mesothelioma 30.9 VIM PECAM1 PDPN
15 hemangioendothelioma 30.9 FLT4 CD34
16 hemangioma 30.8 VIM VEGFA PROX1 PECAM1 PDPN LYVE1
17 primary lymphedema 30.6 VEGFC FLT4
18 congenital lymphedema 30.6 VEGFC PDPN FLT4
19 lipomatosis, multiple 30.6 SERPINA3 PECAM1 CD34
20 kaposiform hemangioendothelioma 30.6 PROX1 PECAM1 KDR FLT4 CD34
21 adenocarcinoma 30.5 VEGFC VEGFA PIK3CA KDR EGFR
22 lymphangioleiomyomatosis 30.5 VEGFC VEGFA PDPN EGFR
23 lymphangiosarcoma 30.5 PROX1 PECAM1 PDPN LYVE1 FLT4 CD34
24 epithelioid hemangioendothelioma 30.4 VEGFA KDR ACTC1
25 angiosarcoma 30.4 VIM VEGFA PROX1 PECAM1 PDPN KDR
26 filariasis 30.4 VEGFA IFNG FLT4
27 epithelial-myoepithelial carcinoma 30.4 VIM PIK3CA ACTC1
28 myoepithelial carcinoma 30.4 VIM PIK3CA ACTC1
29 lymphocele 30.4 VEGFC LYVE1
30 glomus tumor 30.3 VIM CD34 ACTC1
31 chylothorax, congenital 30.3 VEGFC PROX1 LYVE1 FLT4
32 congenital fibrosarcoma 30.3 VIM SERPINA3 ACTC1
33 hobnail hemangioma 30.3 PECAM1 PDPN FLT4 CD34
34 myofibroma 30.3 SERPINA3 MIR143 CD34
35 angiokeratoma circumscriptum 30.3 VEGFA PECAM1 KDR CD34
36 squamous cell carcinoma 30.3 VEGFC VEGFA PIK3CA PDPN EGFR
37 intravascular papillary endothelial hyperplasia 30.3 VIM VEGFA SERPINA3 ACTC1
38 acquired immunodeficiency syndrome 30.3 PECAM1 IFNG IFNA2 CD34 CCR6
39 rhabdomyosarcoma 30.2 VIM VEGFA PIK3CA KDR EGFR ACTC1
40 neurofibroma 30.2 VIM VEGFA EGFR CD34 ACTC1
41 gorham's disease 30.2 VEGFC VEGFA PECAM1 PDPN LYVE1 IFNA2
42 pleomorphic lipoma 30.2 SERPINA3 CD34
43 inflammatory breast carcinoma 30.2 PROX1 LYVE1 EGFR
44 leiomyosarcoma 30.2 VIM VEGFA SERPINA3 PECAM1 ACTC1
45 microinvasive gastric cancer 30.2 VEGFC PDPN MIR20A
46 cystadenocarcinoma 30.2 VIM VEGFC VEGFA SERPINA3 PIK3CA PDPN
47 hemangioma of spleen 30.1 PECAM1 CD34
48 penile cancer 30.1 PIK3CA PDPN EGFR
49 lymphangitis 30.1 VEGFC PROX1 PECAM1 PDPN LYVE1 FLT4
50 arteriovenous malformations of the brain 30.1 VEGFA PECAM1 KDR EGFR

Comorbidity relations with Lymphangioma via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Lymphangioma:



Diseases related to Lymphangioma

Symptoms & Phenotypes for Lymphangioma

GenomeRNAi Phenotypes related to Lymphangioma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 8.8 VIM
2 Decreased cell migration GR00055-A-3 8.8 EGFR PIK3CA

MGI Mouse Phenotypes related to Lymphangioma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.25 ACTC1 EGFR FLT4 IFNG KDR LYVE1
2 homeostasis/metabolism MP:0005376 10.24 ACTC1 CCR6 CD34 EGFR FLT4 IFNG
3 hematopoietic system MP:0005397 10.18 ACTC1 CCR6 CD34 EGFR IFNG KDR
4 immune system MP:0005387 10.17 CCR6 CD34 EGFR FLT4 IFNG KDR
5 integument MP:0010771 9.91 CD34 EGFR FLT4 IFNG KDR PDPN
6 muscle MP:0005369 9.9 ACTC1 EGFR FLT4 IFNG KDR PDPN
7 normal MP:0002873 9.61 ACTC1 CCR6 EGFR FLT4 IFNG KDR
8 respiratory system MP:0005388 9.23 EGFR IFNG KDR PDPN PECAM1 PROX1

Drugs & Therapeutics for Lymphangioma

Drugs for Lymphangioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 29)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Picibanil Phase 4
2
Sodium citrate Approved, Investigational Phase 2 68-04-2
3
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
4
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
5
Sirolimus Approved, Investigational Phase 2 53123-88-9 6436030 5284616
6
tannic acid Approved Phase 2 1401-55-4
7
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
8
Octreotide Approved, Investigational Phase 2 83150-76-9 6400441 383414
9
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
10 Vasodilator Agents Phase 2
11 Citrate Phase 2
12 Phosphodiesterase Inhibitors Phase 2
13 Phosphodiesterase 5 Inhibitors Phase 2
14 Sildenafil Citrate Phase 2 171599-83-0
15 Antibiotics, Antitubercular Phase 2
16 Pharmaceutical Solutions Phase 2
17 Immunologic Factors Phase 2
18 Immunosuppressive Agents Phase 2
19 Anti-Bacterial Agents Phase 2
20 Anti-Infective Agents Phase 2
21 Antifungal Agents Phase 2
22 Antineoplastic Agents, Hormonal Phase 2
23 Gastrointestinal Agents Phase 2
24
Selenium Approved, Investigational, Vet_approved Phase 1 7782-49-2
25 Trace Elements Phase 1
26 Nutrients Phase 1
27 Protective Agents Phase 1
28 Antioxidants Phase 1
29 Micronutrients Phase 1

Interventional clinical trials:

(show all 16)
# Name Status NCT ID Phase Drugs
1 OK432 (Picibanil) in the Treatment of Lymphatic Malformations Completed NCT03427619 Phase 4 OK432
2 Treatment of Cystic Hygroma (Lymphangiomas) in Children- Picibanil(OK432) Sclerotherapy-Multicenter Trial Completed NCT00010452 Phase 2, Phase 3 picibanil
3 A Phase 2 Study - Clinical Trial Assessing Efficacy and Safety of the mTOR Inhibitor Sirolimus in the Treatment of Complicated Vascular Anomalies Unknown status NCT00975819 Phase 2 sirolimus
4 An Investigational Pilot Study to Evaluate Sildenafil for the Treatment of Lymphatic Malformations Completed NCT01290484 Phase 1, Phase 2 Sildenafil
5 TOPical Sirolimus in linGUal Microcystic Lymphatic Malformation -TOPGUN Recruiting NCT04128722 Phase 2 Sirolimus Oral Liquid Product 1mg/mL
6 Phase 2 Study of Sildenafil for the Treatment of Lymphatic Malformations Recruiting NCT02335242 Phase 2 Sildenafil 20 mg tablets
7 Evaluation of the Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations of Poor Prognosis Recruiting NCT03243019 Phase 2 rapamycin
8 0.1% Topical Sirolimus in the Treatment of Cutaneous Microcystic Lymphatic Malformations in Children and Adults: Phase II, Split-body Randomized, Double-blind, Vehicle-controlled Clinical Trial Recruiting NCT03972592 Phase 2 Topical 0.1% Sirolimus;Topical Vehicle
9 Prospective Randomized, Double-blind, Placebo-controlled Parallel Group Study of the Efficacy of Octreotide in Prevention of Salivary Fistulae After Post Radiation Salvage Surgery Recruiting NCT02437825 Phase 2 octreotide
10 Open-Label, Intra Subject, Dose Escalation (Part 1) Followed by Randomized, Double Blind, Placebo Controlled (Part 2) Trial of Topical VT30 in Pts With Venous, Lymphatic or Mixed Malformations Associated With PIK3CA or TEK Genetic Mutations Recruiting NCT04409145 Phase 1, Phase 2 VT30
11 Application of 68Ga NEB PET Imaging in the Diagnosis and Evaluation of Lymphatic Disorders, Including Lymphedema, Lymphangioma, Lymphangioleiomyomatosis, Plastic Bronchitis, Lymphadenopathy Caused by Rheumatoid Arthritis, Etc. Recruiting NCT04273334 Phase 1 68Ga-NEB
12 Pilot Clinical Trial to Estimate the Safety and Efficacy of Selenium in the Treatment of Complicated Lymphatic Malformations in Adolescents and Young Adults Terminated NCT01212965 Phase 1 Selenium
13 Diagnosis of Hemangiomas and Vascular Malformations Using Non-invasive Imaging Devices Completed NCT00577213
14 Airway Vascular Lesions Completed NCT00866827
15 Lymphatic Anomalies Registry for the Assessment of Outcome Data Recruiting NCT02399527
16 INST UNM 1601: Compassionate Use of BYL 719 Alpelisib Available NCT03941782 Alpelisib

Search NIH Clinical Center for Lymphangioma

Cochrane evidence based reviews: lymphangioma

Genetic Tests for Lymphangioma

Genetic tests related to Lymphangioma:

# Genetic test Affiliating Genes
1 Lymphangioma 29
2 Lymphatic Malformation 29

Anatomical Context for Lymphangioma

MalaCards organs/tissues related to Lymphangioma:

40
Endothelial, Tongue, Pancreas, Spleen, Colon, Adrenal Gland, Small Intestine

Publications for Lymphangioma

Articles related to Lymphangioma:

(show top 50) (show all 4369)
# Title Authors PMID Year
1
VEGF-C and VEGFR-3 in a series of lymphangiomas: is superficial lymphangioma a true lymphangioma? 61 54
19151999 2009
2
Elevated expression of VEGFR-3 in lymphatic endothelial cells from lymphangiomas. 54 61
17584927 2007
3
Co-expression of VEGF-C and its receptors, VEGFR-2 and VEGFR-3, in endothelial cells of lymphangioma. Implication in autocrine or paracrine regulation of lymphangioma. 61 54
11742043 2001
4
Orbital lymphangioma with positive immunohistochemistry of lymphatic endothelial markers (vascular endothelial growth factor receptor 3 and podoplanin). 54 61
11585321 2001
5
Lymphangioma of large intestine: report of ten cases with endoscopic and pathologic correlation. 54 61
10922105 2000
6
Intrapericardial lymphangioma with podoplanin immunohistochemical characterization of lymphatic endothelial cells. 61 54
10931742 2000
7
Immunoelectron microscopic characterization of human dermal lymphatic microvascular endothelial cells. Differential expression of CD31, CD34, and type IV collagen with lymphatic endothelial cells vs blood capillary endothelial cells in normal human skin, lymphangioma, and hemangioma in situ. 61 54
9446823 1998
8
Giant esophageal hemangioma diagnosed by 99mTc-HSA-D scintigraphy following equivocal CT, MRI, and endoscopy. 61
33680270 2021
9
Extraskeletal Ewing sarcoma of the buccal space. 61
33360836 2021
10
A rare case report of giant de novo cervical cystic hygroma in an elderly patient: Case report. 61
33747502 2021
11
Prenatal Imaging Findings Predict Obstructive Fetal Airways Requiring EXIT. 61
32770766 2021
12
Neoadjuvant Everolimus for Adult Giant Mesenteric Cystic Lymphangioma with mTOR Pathway Activation. 61
33797168 2021
13
Chylopericardium Due to Residual Lymphangiomyoma Detected on 99mTc-Sulfur Colloid Lymphoscintigraphy. 61
33323742 2021
14
Resection of an axillary macrocystic lymphatic malformation in a 14-year-old girl using intraoperative indocyanine green lymphography. 61
32325148 2021
15
A case of cystic lymphatic malformation mimicking acute appendicitis in an adult patient: a rare diagnostic pitfall. 61
33692052 2021
16
A novel method for isolating lymphatic endothelial cells from lymphatic malformations and detecting PIK3CA somatic mutation in these isolated cells. 61
32876734 2021
17
Fetal therapy using rapamycin for a rapidly enlarging, obstructive, cervical lymphatic malformation: a case report. 61
33742439 2021
18
Cystic lymphangioma in adult-a rare case scenario or a misdiagnosis? 61
33747431 2021
19
Cystic lymphangioma of the greater omentum treated by laparoscopic resection. 61
33782862 2021
20
Mesenteric cystic lymphangioma: A case report. 61
33636409 2021
21
Metastasis of primary breast angiosarcoma to axillary and supraclavicular lymph nodes: a rare case diagnosed using imaging data. 61
33784853 2021
22
Vascular neoplasms and non-neoplastic vascular lesions of the spleen. 61
32674844 2021
23
Gorham-Stout Disease Resulting in Spinal Deformity Treated by Fusion Surgery Combined With Everolimus Therapy: A Case Report. 61
33657060 2021
24
Klippel-Trenaunay syndrome in a young patient with the involvement of gastrointestinal and genitourinary tracts: an unusual and rare presentation. 61
33653847 2021
25
Myopericytoma in right inguinal region: A rare case report from Nepal. 61
33774449 2021
26
Retroperitoneal cystic lymphangioma-a case report. 61
33437648 2021
27
Efficacy and Clinical Outcomes of Bleomycin in the Treatment of Lymphangiomas: A Multicenter Experience. 61
33625132 2021
28
Diagnostic value of echocardiography in paracardiac cystic lesions: 43 cases from one single medical center. 61
33620608 2021
29
Successful Treatment of Vaginal and Pelvic Microcystic Lymphatic Malformation with 50% Ethanol Injection via Lymph Node Angiography. 61
32896619 2021
30
Intra-abdominal lymphatic malformation management in light of the updated International Society for the Study of Vascular Anomalies classification. 61
33559726 2021
31
Painful Abdominal Lump in the Pediatric Age Group: A Diagnostic Dilemma. 61
33728165 2021
32
Condyloma acuminata mimicking cutaneous microcystic lymphatic malformation. 61
33666056 2021
33
Lymphatic and Mixed Malformations. 61
33493408 2021
34
Intranodal lymphangiography and interstitial lymphatic embolization to treat chyluria caused by a lymphatic malformation in a pediatric patient. 61
33638694 2021
35
Skin-Related complications of Klippel-Trenaunay Syndrome: a retrospective review of 410 patients. 61
33070382 2021
36
Severe adverse events during sirolimus "off-label" therapy for vascular anomalies. 61
33580918 2021
37
Splenic Primary Solid Tumors : Does a Preoperative Histopathology Diagnosis Really Matter? 61
32936005 2021
38
A case of lymphangioma circumscriptum with new reflectance confocal microscopy findings. 61
33606271 2021
39
A rare case of retroperitoneal lymphangioma in a 74-year-old Chinese male. 61
33708376 2021
40
Case of feeding disorder due to lymphangioma of the tongue: Importance in developing countries. 61
33522640 2021
41
Cystic lymphangioma of the hepatoduodenal ligament: a rare intra-abdominal tumor mimicking hematoma. 61
32996113 2021
42
Cutaneous pedunculated lymphangioma in a dog. 61
33522616 2021
43
Abdominal cystic lymphangioma mimicking ovarian mass: A case report and literature review. 61
33437481 2021
44
Recurrent Leiomyosarcoma With Malignant Transformation. 61
33604210 2021
45
A rare cause of intra-abdominal cysts: pancreatic cystic lymphangiomas. 61
33393336 2021
46
Comparison of sonographic findings between neonates with pyriform sinus fistulas and lymphangiomas. 61
33125899 2021
47
Net-like superficial lymphatic malformation. 61
33486776 2021
48
Generalized lymphangiomatosis-A rare manifestation of lymphatic malformation. 61
33193931 2021
49
Combined endolymphatic and surgical treatment of a leaking central conducting lymphatic malformation in a neonate. 61
33250948 2021
50
Acquired lymphangioma circumscriptum in high-grade penile intraepithelial neoplasia. 61
33121365 2021

Variations for Lymphangioma

Expression for Lymphangioma

Search GEO for disease gene expression data for Lymphangioma.

Pathways for Lymphangioma

Pathways related to Lymphangioma according to KEGG:

36
# Name Kegg Source Accession
1 MAPK signaling pathway hsa04010
2 Focal adhesion hsa04510
3 PI3K-Akt signaling pathway hsa04151
4 Rap1 signaling pathway hsa04015

Pathways related to Lymphangioma according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.49 VEGFC VEGFA PIK3CA KDR IFNG IFNA2
2
Show member pathways
13.24 VEGFC VEGFA SERPINA3 PIK3CA PECAM1 PDPN
3
Show member pathways
12.87 VEGFC VEGFA PIK3CA KDR IFNA2 FLT4
4
Show member pathways
12.84 VEGFC VEGFA PIK3CA KDR FLT4 EGFR
5 12.7 VEGFC VEGFA PIK3CA IFNG IFNA2 FLT4
6 12.69 VEGFC VEGFA KDR FLT4 EGFR
7
Show member pathways
12.63 VEGFC VEGFA PIK3CA KDR FLT4 EGFR
8
Show member pathways
12.44 VEGFC VEGFA PIK3CA KDR EGFR
9
Show member pathways
12.36 PIK3CA IFNG IFNA2 EGFR
10
Show member pathways
12.34 VEGFC PIK3CA KDR FLT4 EGFR
11
Show member pathways
12.34 VEGFC VEGFA KDR FLT4 EGFR
12 12.33 VEGFC VEGFA KDR FLT4 EGFR
13
Show member pathways
12.31 VEGFC VEGFA PIK3CA KDR FLT4 EGFR
14 12.23 VEGFA PIK3CA KDR EGFR
15 12.19 VIM VEGFA PIK3CA MIR20A MIR18A MIR143
16
Show member pathways
12.16 VEGFC KDR IFNG IFNA2 FLT4 EGFR
17 12.07 VEGFC KDR FLT4 EGFR
18 12.01 VIM VEGFA PROX1 KDR
19 11.94 VEGFA PIK3CA PECAM1 KDR IFNG
20 11.91 VEGFA PIK3CA IFNG EGFR
21
Show member pathways
11.75 PIK3CA KDR FLT4
22 11.73 IFNG CD34 CCR6
23 11.68 IFNG IFNA2 CD34
24
Show member pathways
11.62 VEGFC VEGFA PIK3CA KDR FLT4
25 11.48 VEGFA PIK3CA KDR
26 11.44 VEGFA PIK3CA KDR
27 11.3 VEGFA KDR FLT4 EGFR
28
Show member pathways
11.25 VEGFA PIK3CA KDR EGFR
29 11.09 VEGFA PIK3CA KDR
30 11.06 VEGFC PIK3CA FLT4
31 11.05 VEGFC PROX1 PECAM1 PDPN KDR FLT4
32 10.59 VEGFC VEGFA
33
Show member pathways
10.46 VEGFC VEGFA KDR FLT4

GO Terms for Lymphangioma

Cellular components related to Lymphangioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane raft GO:0045121 9.56 PECAM1 PDPN KDR EGFR
2 integral component of plasma membrane GO:0005887 9.56 PECAM1 PDPN LYVE1 KDR FLT4 EGFR
3 extracellular space GO:0005615 9.36 VEGFC VEGFA SERPINA3 PECAM1 MIR20A MIR18A
4 platelet alpha granule lumen GO:0031093 9.33 VEGFC VEGFA SERPINA3

Biological processes related to Lymphangioma according to GeneCards Suite gene sharing:

(show all 42)
# Name GO ID Score Top Affiliating Genes
1 multicellular organism development GO:0007275 10.19 VEGFC VEGFA PROX1 PDPN KDR FLT4
2 positive regulation of gene expression GO:0010628 10.07 VIM VEGFA IFNG CD34 ACTC1
3 positive regulation of cell proliferation GO:0008284 10.05 VEGFC VEGFA PROX1 KDR IFNG FLT4
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.96 VEGFA KDR FLT4 EGFR
5 angiogenesis GO:0001525 9.95 VEGFC VEGFA PIK3CA KDR FLT4
6 negative regulation of gene expression GO:0010629 9.95 VEGFA MIR20A KDR IFNG IFNA2 CD34
7 positive regulation of protein kinase B signaling GO:0051897 9.94 VEGFA PIK3CA MIR143 EGFR
8 cell-cell adhesion GO:0098609 9.93 PECAM1 PDPN EGFR CD34
9 positive regulation of cell migration GO:0030335 9.88 VEGFC VEGFA PECAM1 PDPN KDR EGFR
10 platelet degranulation GO:0002576 9.87 VEGFC VEGFA SERPINA3 PECAM1
11 liver development GO:0001889 9.86 PROX1 PIK3CA EGFR
12 positive regulation of kinase activity GO:0033674 9.84 KDR FLT4 EGFR
13 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.84 VEGFA IFNG IFNA2
14 lung development GO:0030324 9.84 VEGFA PROX1 PDPN EGFR
15 positive regulation of epithelial cell proliferation GO:0050679 9.83 VEGFC VEGFA EGFR
16 positive regulation of endothelial cell migration GO:0010595 9.83 VEGFA PROX1 KDR FLT4
17 humoral immune response GO:0006959 9.82 IFNG IFNA2 CCR6
18 positive regulation of blood vessel endothelial cell migration GO:0043536 9.76 VEGFC VEGFA MIR143 KDR
19 sprouting angiogenesis GO:0002040 9.75 VEGFC VEGFA FLT4
20 positive regulation of phosphorylation GO:0042327 9.73 VEGFA IFNA2 EGFR
21 positive regulation of angiogenesis GO:0045766 9.73 VEGFC VEGFA MIR20A MIR143 KDR CD34
22 positive regulation of endothelial cell proliferation GO:0001938 9.72 VEGFC VEGFA PROX1 KDR FLT4
23 positive regulation of vasculogenesis GO:2001214 9.68 KDR CD34
24 positive regulation of positive chemotaxis GO:0050927 9.68 VEGFA KDR
25 lymph vessel development GO:0001945 9.68 PROX1 FLT4
26 positive regulation of protein kinase C signaling GO:0090037 9.67 VEGFA FLT4
27 positive regulation of cellular component movement GO:0051272 9.67 VEGFA PDPN
28 lymphangiogenesis GO:0001946 9.67 PROX1 PDPN FLT4
29 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.67 VEGFA MIR20A KDR FLT4
30 positive regulation of mast cell chemotaxis GO:0060754 9.64 VEGFC VEGFA
31 skeletal muscle thin filament assembly GO:0030240 9.63 PROX1 ACTC1
32 aorta smooth muscle tissue morphogenesis GO:0060414 9.62 PROX1 MIR143
33 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.62 VEGFA KDR
34 vascular endothelial growth factor receptor-2 signaling pathway GO:0036324 9.61 VEGFA KDR
35 endothelium development GO:0003158 9.61 KDR CD34
36 vascular wound healing GO:0061042 9.61 VEGFA KDR CD34
37 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.6 MIR20A MIR143
38 glomerular endothelium development GO:0072011 9.59 PECAM1 CD34
39 lymphatic endothelial cell fate commitment GO:0060838 9.58 PROX1 PDPN
40 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.55 VEGFC VEGFA PIK3CA KDR FLT4
41 positive regulation of protein phosphorylation GO:0001934 9.5 VEGFC VEGFA PECAM1 KDR IFNG FLT4
42 vascular endothelial growth factor signaling pathway GO:0038084 9.02 VEGFC VEGFA PIK3CA KDR FLT4

Molecular functions related to Lymphangioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 vascular endothelial growth factor-activated receptor activity GO:0005021 9.16 KDR FLT4
2 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.13 KDR FLT4 EGFR
3 vascular endothelial growth factor receptor binding GO:0005172 8.62 VEGFC VEGFA

Sources for Lymphangioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....